SCHEMBL1680712

SCHEMBL1680712

CCCOCCc1ccc(C#N)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ LOXL2 Q9Y4K0 2/20 0.46
▸ KCNJ1 P48048 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ MAOA P21397 2/20 0.42
▸ MAOB P27338 2/20 0.42
▸ CYP19A1 P11511 4/20 0.41
▸ PTGES O14684 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ PPARD Q03181 2/20 0.39
▸ PPARA Q07869 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11102988 0.95 TSHR (0.61) CYP2A6TSHRHSD17B10LOXL2KCNJ1
SCHEMBL11617640 0.90 LOXL2 (0.52) CYP2A6TSHRHSD17B10LOXL2KCNJ1
SCHEMBL13344429 0.87 CYP2A6 (0.55) CYP2A6TSHRHSD17B10LOXL2KCNJ1
SCHEMBL11104834 0.85 TSHR (0.67) CYP2A6TSHRHSD17B10PTGESALOX5
SCHEMBL11103383 0.84 TSHR (0.69) CYP2A6TSHRHSD17B10CYP19A1PTGES
SCHEMBL24685293 0.83 CYP2A6 (0.55) CYP2A6TSHRHSD17B10LOXL2MAOA
SCHEMBL11110617 0.82 TSHR (0.72) CYP2A6TSHRHSD17B10CYP19A1ALDH1A1
SCHEMBL11100351 0.82 TSHR (0.72) CYP2A6TSHRHSD17B10CYP19A1ALDH1A1
SCHEMBL11109906 0.82 TSHR (0.72) CYP2A6TSHRHSD17B10CYP19A1ALDH1A1
SCHEMBL11103216 0.82 TSHR (0.72) CYP2A6TSHRHSD17B10CYP19A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 — — US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 — — US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 — — US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 — — US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 — — US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 — — US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 — — US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 — — EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 CYP2A6 1051/4885TSHR 3875/4885HSD17B10 3209/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD CYP2A6 2188/4885TSHR 3836/4885HSD17B10 3600/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 CYP2A6 1103/4885TSHR 3952/4885HSD17B10 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback